Related Experiment Video
Updated: Jun 23, 2025
10:13
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.1K
GAS-Luc2 Reporter Cell Lines for Immune Checkpoint Drug Screening in Solid Tumors.
Hyeyoun Chang1, John G Foulke1, Luping Chen1
1American Type Culture Collection (ATCC), Manassas, VA 20110, USA.
Cancers
|June 19, 2024
Summary
This study introduces a novel reporter system for evaluating immune checkpoint inhibitors. The engineered cells enable efficient ex vivo drug screening by measuring T cell-mediated tumor cell death and interferon gamma signaling.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- The interferon gamma receptor (IFNγR) pathway is crucial for T cell cytotoxicity against solid tumors.
- Ex vivo screening of immune checkpoint drugs using human cell lines is challenging.
- Immune checkpoints regulate T cell activity and tumor immune evasion.
Purpose of the Study:
- To develop and validate an engineered reporter system for ex vivo immune checkpoint drug screening.
- To utilize a gamma interferon activation site response element luciferase reporter (GAS-Luc2) for quantifying drug efficacy.
- To engineer tumor cell lines expressing key immune checkpoints for co-culture assays.
Main Methods:
- Engineered GAS-Luc2 reporter tumor cell lines expressing PD-L1, CD155, or B7-H3/CD276.
- Profiling of cell surface proteins to identify suitable cell lines for engineering.
- Co-culture assays with T cells and reporter tumor cells in the presence of immune checkpoint inhibitors.
- Measurement of bioluminescent signals generated by the GAS-Luc2 reporter system.
- Development of artificial antigen-presenting cells (aAPCs) to enhance T cell signaling.
Main Results:
- Engineered reporter cell lines demonstrated suppressed luciferase expression upon immune checkpoint-ligand engagement.
- The system successfully quantified interferon gamma (IFNγ) release from T cells upon inhibitor treatment.
- Reporter lines detected paracrine IFNγ signaling for antibody-dependent cell-mediated cytotoxicity (ADCC) drug screening.
- Artificial antigen-presenting cells significantly enhanced T cell signaling for improved screening performance.
Conclusions:
- The GAS-Luc2 reporter system provides a robust platform for ex vivo immune checkpoint drug screening.
- This approach facilitates the evaluation of T cell-mediated cytotoxicity and IFNγ signaling in response to novel therapeutics.
- The engineered cell lines and aAPC technology offer a promising avenue for advancing cancer immunotherapy drug development.
